You are here: Industry Insights > Xarelto

News List

FDA approves drug to treat, help prevent types of blood clots in certain pediatric populations FDA
December 22, 2021
FDA has approved Xarelto (rivaroxaban) as tablets and an oral suspension to treat venous thromboembolism (VTE), or blood clots that form in the veins, and reduce the risk of VTE recurring in pediatric patients...
Bayer reports steady 2020 performance despite Covid-19 pandemic pharmaceutical-technology
February 26, 2021
German-headquartered pharma company Bayer has published its 2020 annual report. The report suggests that Bayer had a robust 2020 despite the Covid-19 pandemic and there was positive momentum for solid operational growth in 2021, the company said.
Bayer’s Xarelto approved in the UK pharmatimes
February 02, 2021
Bayer’s oral factor Xa inhibitor Xarelto (rivaroxaban) has been approved in the UK to treat venous thromboembolism (VTE) and to prevent VTE recurrence in children.
Janssen Submits sNDA for Expanded Use of XARELTO americanpharmaceuticalreview
October 30, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with ...
Bayer's Q1 sales boosted by performance of Xarelto, Eylea, while profit held back by acquisition, restructuring costs firstwordpharma
April 26, 2019
CEO Werner Baumann noted that the pharmaceutical division "delivered encouraging performance."
Discounting hit J&J's Xarelto hard. Can a new launch turn things around? fiercepharma
January 23, 2019
Competition and discounting are understandably plaguing Johnson & Johnson's older drugs. But its cardiovascular blockbuster Xarelto is also on that list.
J&J makes Xarelto case for clot prevention in cancer fiercepharma
December 06, 2018
SAN DIEGO—Johnson & Johnson's clot-busting Xarelto may not have hit the primary goal in its latest trial...
Bayer, J&J’s heart drug Xarelto fails trial to widen use expressbpd
August 28, 2018
The blockbuster clot prevention drug could not be shown to reduce the rate of dangerous blood clots in a certain group of high-risk patients after discharge from hospital
Bayer, Johnson & Johnson's heart drug Xarelto fails trial to widen use firstwordpharma
August 27, 2018
Study data published in the NEJM reveal that Bayer and Johnson & Johnson's cardiovascular drug Xarelto did not reduce the rate of blood clots in certain high-risk patients, as reported Channel News Asia Sunday.
New dosing for Janssen's Xarelto approved by FDA to reduce the risk of VTE europeanpharmaceuticalreview
October 31, 2017
The FDA has approved the 10 mg once-daily dose of Xarelto, for reducing the continued risk of VTE.

Previous page 1 2 Next page